<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340427</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3455-I-02</org_study_id>
    <nct_id>NCT04340427</nct_id>
  </id_info>
  <brief_title>A Study of TQB3455 Tablets in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase I Study of TQB3455 Tablets in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics
      of TQB3455 tablets in subjects with advanced malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>Subjects appear the toxic reaction relate to the drug after treatment within 28 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0, 1, 2, 3, 5, 8, 10, 12, 24, 48, 72, 96, 120, 144 hours post-dose on single dose; Hour 0 of day 8, day 15, day22 on multiple dose and hour 0, 1, 2, 3, 5, 8, 10, 12, 24 hours post-dose on multiple dose of day 28.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQB3455 or metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hour 0, 1, 2, 3, 5, 8, 10, 12, 24, 48, 72, 96, 120, 144 hours post-dose on single dose; Hour 0 of day 8,day 15,day22 on multiple dose and hour 0, 1, 2, 3, 5, 8, 10, 12, 24 hours post-dose on multiple dose of day 28.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3455 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Hour 0, 1, 2, 3, 5, 8, 10, 12, 24, 48, 72, 96, 120, 144 hours post-dose on single dose; Hour 0 of day 8,day 15,day22 on multiple dose and hour 0, 1, 2, 3, 5, 8, 10, 12, 24 hours post-dose on multiple dose of day 28.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3455 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>α-Hydroxyglutaric acid (2-HG)</measure>
    <time_frame>Day 1, Day 8 and Day 15 pre-dose on cycle 1; Day1, Day15 pre-dose on cycle 2 and cycle 3; Day 1 pre-dose on multiple dose from cycle 4 to cycle 8. Each cycle is 28 days.</time_frame>
    <description>The concentration of 2-HG.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>TQB3455 Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3455 Tablet administered orally once. Then TQB3455 Tablet administered orally, once daily in 28-day cycle after 7 days of first administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3455</intervention_name>
    <description>TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.</description>
    <arm_group_label>TQB3455 Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. ≥ 18 years old； Eastern Cooperative Oncology Group (ECOG) performance status score
             of 0 to 2; Life expectancy ≥12 weeks.

             2. Has IDH2 gene mutation will be selected preferentially. 3. The toxicity of
             radiotherapy or other antitumor therapy should return to grade 1.

             4. No pregnant or lactating women, all the participants should use contraceptives.

             5. Understood and signed an informed consent form. 6. Advanced/metastatic solid tumors
             or refractory/recurrent acute myeloid leukemia.

             7. At least one measurable lesion for solid tumors. 8. Adequate organ system function.

        Exclusion Criteria:

          -  1.Relapsed after bone marrow transplantation. 2.Has received systemic antitumor
             therapy or radiation therapy within 3 weeks before the first dose.

             3.Has participated in other clinical trial within four weeks before the first dose.

             4.Has multiple factors affecting oral medication. 5.Has uncontrolled, active systemic
             fungal, bacterial, or viral infections. 6.Poorly controlled hypertension. 7.Has
             serious cardiovascular disease. 8.Has drug abuse history that unable to abstain from
             or mental disorders. 9.Has active hepatitis B or C. 10.Have a history of
             immunodeficiency. 11.According to the judgement of the researchers, there are other
             factors that subjects are not suitable for the study.

             12.Has central nervous system metastasis with the exception of glioma subjects. 13.Has
             severe life-threatening complication of leukemia, such as uncontrolled bleeding,
             hypoxia or shock pneumonia, and disseminated intravascular coagulation.

             14.Has central nervous system leukemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weiqi Nian</last_name>
    <phone>023-65079277</phone>
    <email>nwqone@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiqi Nian, M.D.</last_name>
      <phone>023-65079277</phone>
      <email>nwqone@126.com</email>
    </contact>
    <investigator>
      <last_name>Weiqi Nian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

